Chlorpromazine Hydrochloride Injection
NDC Package 70771-1779-7
Package Information
Chlorpromazine Hydrochloride injection is classified as a
administered via intramuscular route. This formulation utilizes a injection delivery system. Marketed by Zydus Lifesciences Limited, this product is identified by NDC 70771-1779 and is authorized under FDA application ANDA217275.Identification & Billing
- RxCUI: 1730076 - chlorproMAZINE HCl 25 MG in 1 ML Injection
- RxCUI: 1730076 - 1 ML chlorpromazine hydrochloride 25 MG/ML Injection
- RxCUI: 1730076 - chlorpromazine HCl 25 MG per 1 ML Injection
- RxCUI: 1730078 - chlorproMAZINE HCl 50 MG in 2 ML Injection
- RxCUI: 1730078 - 2 ML chlorpromazine hydrochloride 25 MG/ML Injection
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 70771 - Zydus Lifesciences Limited
- 70771-1779 - Chlorpromazine Hydrochloride
- 70771-1779-7 - 25 VIAL in 1 CARTON / 2 mL in 1 VIAL (70771-1779-1)
- 70771-1779 - Chlorpromazine Hydrochloride
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 70771-1779-7 identifies a specific commercial package of 25 vial in 1 carton / 2 ml in 1 vial (70771-1779-1) of Chlorpromazine Hydrochloride, a human prescription drug labeled by Zydus Lifesciences Limited. This injection is formulated for intramuscular use and contains chlorpromazine hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Zydus Lifesciences Limited on March 29, 2024. The current certification is valid through December 31, 2026.
How is this Zydus Lifesciences Limited product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 70771177907. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.